(Total Views: 345)
Posted On: 06/03/2020 6:30:23 PM
Post# of 112
NetworkNewsBreaks – Cannabis Global, Inc. (MCTC) Discusses Strong Solution with Expected 50%+ Cost Advantage in Production of THC-V and Other Rare Cannabinoids
Cannabis Global (OTC: MCTC), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, today announced information on its Project Varin, a nearly complete research program implemented to develop novel production technologies for rare cannabinoids, including tetrahydrocannabivarin (“THC-V”), which is not scheduled at the federal level. According to the update, the program has produced meaningful technology breakthroughs resulting in several patent filings. The company has been able to leverage these technological developments to significantly reduce the cost of exotic cannabinoids on a per-serving basis resulting in a greater than 50% expected cost advantage. “We think we have rewritten the exotic cannabinoid cost equation via our Project Varin. The minor exotics represent a new cost challenge for the industry, and we believe we have developed a strong and defensible solution,” Arman Tabatabaei, CEO of Cannabis Global, stated in the news release. “Acquiring THC and CBD from plants within the Cannabaceae family is relatively easy as these cannabinoids are produced by nature in abundance. It is a very different issue relative to THC-V, CBN, and other exotics. With our patent pending technologies, we have been able to rewrite the cost equation for minor cannabinoids, while at the same time moving well beyond the purity possible from legacy technologies. While we are already at a 50% cost advantage to the competing technologies, most of which are still theoretical and not yet available on the market, we believe further travel down our cost curve is possible as we move into high volume manufacturing this month.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cannabis Global (OTC: MCTC), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, today announced information on its Project Varin, a nearly complete research program implemented to develop novel production technologies for rare cannabinoids, including tetrahydrocannabivarin (“THC-V”), which is not scheduled at the federal level. According to the update, the program has produced meaningful technology breakthroughs resulting in several patent filings. The company has been able to leverage these technological developments to significantly reduce the cost of exotic cannabinoids on a per-serving basis resulting in a greater than 50% expected cost advantage. “We think we have rewritten the exotic cannabinoid cost equation via our Project Varin. The minor exotics represent a new cost challenge for the industry, and we believe we have developed a strong and defensible solution,” Arman Tabatabaei, CEO of Cannabis Global, stated in the news release. “Acquiring THC and CBD from plants within the Cannabaceae family is relatively easy as these cannabinoids are produced by nature in abundance. It is a very different issue relative to THC-V, CBN, and other exotics. With our patent pending technologies, we have been able to rewrite the cost equation for minor cannabinoids, while at the same time moving well beyond the purity possible from legacy technologies. While we are already at a 50% cost advantage to the competing technologies, most of which are still theoretical and not yet available on the market, we believe further travel down our cost curve is possible as we move into high volume manufacturing this month.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
